Context Therapeutics Statistics
Share Statistics
Context Therapeutics has 75.00M shares outstanding. The number of shares has increased by 369.73% in one year.
| Shares Outstanding | 75.00M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 59.22M |
| Failed to Deliver (FTD) Shares | 209 |
| FTD / Avg. Volume | 0.07% |
Short Selling Information
The latest short interest is 1.03M, so 1.37% of the outstanding shares have been sold short.
| Short Interest | 1.03M |
| Short % of Shares Out | 1.37% |
| Short % of Float | 1.73% |
| Short Ratio (days to cover) | 2.79 |
Valuation Ratios
The PE ratio is -0.75 and the forward PE ratio is -7.07.
| PE Ratio | -0.75 |
| Forward PE | -7.07 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 1.52 |
| P/FCF Ratio | -0.86 |
| PEG Ratio | n/a |
Enterprise Valuation
Context Therapeutics Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 3.83, with a Debt / Equity ratio of 0.
| Current Ratio | 3.83 |
| Quick Ratio | 3.83 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -2.02% and return on capital (ROIC) is -211.21%.
| Return on Equity (ROE) | -2.02% |
| Return on Assets (ROA) | -1.49% |
| Return on Capital (ROIC) | -211.21% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -4.79M |
| Employee Count | 5 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 41.84% in the last 52 weeks. The beta is 2.25, so Context Therapeutics 's price volatility has been higher than the market average.
| Beta | 2.25 |
| 52-Week Price Change | 41.84% |
| 50-Day Moving Average | 1.85 |
| 200-Day Moving Average | 1.86 |
| Relative Strength Index (RSI) | 30.42 |
| Average Volume (20 Days) | 298.51K |
Income Statement
In the last 12 months, Context Therapeutics had revenue of $0 and earned -$23.96M in profits. Earnings per share was $-1.5.
| Revenue | 0 |
| Gross Profit | -12.04K |
| Operating Income | -25.07M |
| Net Income | -23.96M |
| EBITDA | -25.06M |
| EBIT | - |
| Earnings Per Share (EPS) | -1.5 |
Balance Sheet
The company has $14.45M in cash and $0 in debt, giving a net cash position of $14.45M.
| Cash & Cash Equivalents | 14.45M |
| Total Debt | 0 |
| Net Cash | 14.45M |
| Retained Earnings | -68.05M |
| Total Assets | 86.33M |
| Working Capital | 83.74M |
Cash Flow
In the last 12 months, operating cash flow was -$21.05M and capital expenditures $0, giving a free cash flow of -$21.05M.
| Operating Cash Flow | -21.05M |
| Capital Expenditures | 0 |
| Free Cash Flow | -21.05M |
| FCF Per Share | -1.32 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
CNTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -107.91% |
| FCF Yield | -20.26% |
Analyst Forecast
The average price target for CNTX is $7.5, which is 439.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $7.5 |
| Price Target Difference | 439.6% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Scores
| Altman Z-Score | 24.65 |
| Piotroski F-Score | 3 |